drugset / Trial / NCT00721344
A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.
RandomizedCrossoverQuadruple-blindTreatment
Summary
48 healthy adult male \& female subjects will be enrolled in this study to determine the effect of Technosphere® Inhalation Powder (FDKP) on the QT interval of the EKG. Eligible subjects will be randomized into a dosing regimen after admission.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-08
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fumaryl Diketopiperazine | Unknown | 20 mg | Inhaled |
| Subject | Fumaryl Diketopiperazine | Unknown | 40 mg | Inhaled |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.